Skip to main content
OpenTrials
Completed

NCT Number: NCT03690427

The Cardiovascular Effects of Electronic Hookah Vaping

Hookah (water-pipe) tobacco smoking has quickly grown to become a major global tobacco epidemic among youth; with electronic (e-) hookahs more recently increasing in popularity especially among young female adults, who endorse marketing claims that these products are a safer alternative to traditional hookah, but scientific evidence is lacking. The study aims to elucidate the comparative effects of traditional hookah smoking vs. e-hookah vaping on human vascular and endothelial function; and examine the role of inflammation and oxidative stress, as likely mechanisms in hookah-related cardiovascular disease pathogenesis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Endothelial Dysfunction Inflammation Oxidative Stress Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

21 year–39 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of California, Los Angeles

Los Angeles, California, 90095-8361, United States

About this study

Hookah (water-pipe) tobacco smoking is rapidly increasing in popularity worldwide. Contributing to this popularity is the unsubstantiated belief that traditional charcoal-heated hookah smoke is detoxified as it passes through the water-filled basin. More recently, electronic (e-) hookahs-containing flavored e-liquid that is heated electrically but inhaled through traditional water-pipes-are increasing in popularity in the United States among young female adults, who endorse marketing claims that these products are even safer than traditional charcoal-heated hookah products. The objective of this project is to investigate the comparative effects of traditional charcoal-heated hookah smoking versus e-hookah vaping on endothelial and vascular function and their mechanistic role in the development of cardiovascular disease. The investigators will test the hypothesis that: 1) in the absence of burning charcoal briquettes and virtually any carbon monoxide (CO) exposure, e-hookah vaping acutely impairs endothelial function and evokes acute central arterial stiffness, opposite from the endothelial function augmentation observed after traditional charcoal-heated hookah smoking, which is likely mediated by the large CO boost emitted from burning charcoal briquettes used to heat the flavored hookah tobacco; and 2) the processes of oxidative stress and inflammation play a pivotal mechanistic role underlying these vascular changes. Accordingly, in a cross-over study comparing traditional hookah smoking to e-hookah vaping, the investigators will assess endothelial function measured by brachial artery flow-mediated dilation and aortic stiffness by pulse wave velocity and augmentation index in 18 young healthy hookah smokers 21-39 years old, before and after ad lib 30-minute smoking/ vaping exposure sessions. To test for oxidative stress mediation, the investigators will determine if any acute impairment in endothelial function after e-hookah can be prevented by intravenous Vitamin C infusion, a potent anti-oxidant. Inflammatory and oxidant biomarkers, as well as smoking exposure biomarkers will be collected before and after the exposure sessions. The results of this proposal: (a) stand to fill in gaps in our mechanistic understanding of the comparative effect of traditional vs. e-hookah bowl on vascular and endothelial function; and (b) help inform policy decisions by the FDA about regulation of hookah products.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 21-39 years old hookah smokers: smoked hookah >12x in last 12 months
  • no history of illicit drugs or marijuana
  • no evidence of cardiopulmonary disease by history/ physical
  • no diabetes: fasting blood glucose <100 mg/dl
  • BP<140/90mmHg
  • resting HR<100 bpm
  • BMI<30kg•m2
  • no prescription medication

Exclusion criteria

  • exhaled CO>10 ppm (smoking non-abstinence)
  • positive pregnancy test
  • psychiatric illness

Treatment and study plan

Traditional hookah smoking

Other

Charcoal-heated hookah smoking

Other names: Combustible hookah smoking

Electronic hookah vaping

Other

Electronic hookah bowl inhalation

Primary outcomes

  1. Flow-Mediated Dilation (FMD)

    Time frame: Pre- and post- the 30-minute smoking or vaping exposure sessions

    Using ultrasound, FMD of the brachial artery induced by reactive hyperemia, was used to measure endothelium-dependent vasodilator function. Baseline diameter and velocity were recorded for 45 seconds and resumed 30 seconds before cuff deflation and continuously for 2 minutes after deflation to obtain true peak vasodilatory response.

  2. Carotid-Femoral Pulse Wave Velocity (Cf-PWV)

    Time frame: Pre- and post- the 30-minute smoking or vaping exposure sessions

    Using applanation tonometry, cf-PWV was used to measure central arterial stiffness.

  3. HDL Oxidant Index (HOI)

    Time frame: Pre- and post- the 30-minute smoking or vaping exposure sessions

    Capacity was determined as the ability of HDL to inhibit LDL-induced oxidation of dihydrodichlorofluorescein into the fluorescent dichlorofluorescein. Capacity was expressed as an HDL oxidative index, determined by the ratio of dichlorofluorescein fluorescence in the presence and absence of HDL. An index of < 1.0 denotes protective antioxidant HDL, whereas an index of > 1.0 indicates pro-oxidant HDL.

  4. Paraoxonase-1 (PON-1) Activity

    Time frame: Pre- and post- the 30-minute smoking or vaping exposure sessions

    PON-1 activity was determined by the ability of PON-1, associated with HDL, to hydrolyze paraoxon substrate. The hydrolysis of paraoxon (diethyl-p-nitrophenyl phosphate) to p-nitrophenol by PON-1 was determined by incubating 5 mL of plasma with 1.0 mM paraoxon in 100 mM tris-HCl buffer (pH, 8.5).

    Unit of Measure: expressed as micromoles of p-nitrophenol formed per minute for every 1 mL plasma.

  5. Arylesterase Activity

    Time frame: Pre- and post- the 30-minute smoking or vaping exposure sessions.

    Arylesterase activity (lipid peroxidation biomarker) was determined by the rate of hydrolysis of phenyl acetate to phenol. Briefly, 4 mL plasma was incubated with 3.5 mM phenyl acetate in 9 mM Tris-HCl buffer (pH, 8.0) containing 0.9 mM CaCl2 at RT. The kinetics of phenol formation were determined by recording the absorbance at 270 nm every 15 s for 2 min.

    Unit of Measure: nanomoles of product formed per minute per milliliter of plasma.

  6. High-sensitivity C-reactive Protein (Hs-CRP) Levels

    Time frame: Pre- and post- the 30-minute smoking or vaping exposure sessions

    Plasma hs-CRP (inflammatory biomarker)

  7. Tumor Necrosis Factor-α (TNFα) Concentrations

    Time frame: Pre- and post- the 30-minute smoking or vaping exposure sessions

    Plasma TNFα (inflammatory biomarker)

Secondary outcomes

  1. Flow-Mediated Dilation (FMD)

    Time frame: Effect of FMD with e-hookah vaping examined after pretreatment of intravenous infusion of antioxidant ascorbic acid (administered over 60 minutes at 0.5 mL min-1)

    Using ultrasound, FMD of the brachial artery, induced by reactive hyperemia, was used to measure endothelium-dependent vasodilator function after intravenous infusion of antioxidant ascorbic acid. Infusion of antioxidant ascorbic acid was done before the e-hookah vaping session.

  2. Endothelium-independent Vasodilator Function (Control Test for Endothelium-dependent Vasodilator Function)

    Time frame: Pre- and post- sublingual administration of nitroglycerin (0.15 mg), which was administrated before and after e-hookah vaping.

    As a control test for the assessment of endothelium-dependent vasodilator function, using ultrasound the brachial artery, endothelium-independent dilatation was assessed by administering sublingual nitroglycerin. This measure was assessed 10 minutes after FMD testing. Ultrasound images were recorded continuously for a total of 10 minutes

  3. Augmentation Index (AI)

    Time frame: Pre- and post- the 30-minute smoking or vaping exposure sessions

    AI was used to measure central stiffness. It was calculated as the ratio of augmentation pressure (difference between the second and first systolic peaks of the aortic pressure waveform) and pulse pressure expressed as a percentage.

  4. Interleukin 6 (IL-6) Levels

    Time frame: A change between two points is reported below (e.g., value at post-exposure session minus value at pre-exposure session).

    Plasma IL-6 (inflammatory biomarker).

  5. Interleukin 10 (IL-10) Levels

    Time frame: A change between two points is reported below (e.g., value at post-exposure session minus value at pre-exposure session).

    Serum IL-10 (anti-inflammatory biomarker)

  6. Nicotine Levels

    Time frame: Pre- and post- the 30-minute smoking or vaping exposure sessions

    Plasma nicotine levels (smoking or vaping exposure biomarker)

  7. Carbon Monoxide (CO) Levels

    Time frame: Pre- and post- the 30-minute smoking or vaping exposure sessions

    Exhaled CO levels (smoking or vaping exposure biomarker)

Sponsors and collaborators

Lead sponsor

University of California, Los Angeles

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)
  • National Institutes of Health (NIH)

Registry information

Official study title

Investigating the Cardiovascular Toxicity of Exposure to Electronic Hookah Smoking

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Oct 1, 2018
Registry last updated
Aug 16, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.